European database and biobank for childhood interstitial lung diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to create a comprehensive European database and biobank for children with interstitial lung diseases (chILD). It will involve the collection of clinical data and biological samples from patients across multiple countries, including France, Germany, and the UK. The initiative will also focus on establishing standardized treatment protocols and guidelines through continuous assessment by a panel of experts. Additionally, it seeks to recruit a well-characterized cohort of chILD patients to enhance understanding and management of these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* all children with suspected or
* verified diagnosis of ILD or
* masquerading as ILD and
* those with rare localized parenchymal lung diseases

Exclusion Criteria:

* other indication as inclusion criteria

Where it's running

• Medizinische Hochschule Hannover
  Hanover, Lower Saxony, Germany Recruiting
• Hacettepe University, Medical Faculty
  Ankara, Sihhiye, Turkey (Türkiye) Recruiting
• University of Edinburgh
  Edinburgh, United Kingdom Recruiting

Study contacts

• Study coordinator: Matthias Griese, Prof.
• Email: Matthias.Griese@med.uni-muenchen.de
• Phone: +49/89/440057871

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital self-management package for people with interstitial lung disease

  This study is testing a new smartphone app designed to help people with interstitial lung disease manage their health better and feel improved overall compared to standard care.

  Recruiting at 4 sites University of Sydney · Sydney, New South Wales and 3 other locations · NCT06122233

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

• Advanced imaging to see how immunosuppression affects lung fibrosis activity

  This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT07572383

• LISA versus endotracheal surfactant distribution in preterm babies

  This pilot trial tests whether giving surfactant through a thin catheter (LISA) or through a breathing tube leads to more even surfactant spread in preterm infants with respiratory distress.

  Recruiting Hamad General Hospital · Doha · NCT07514481

• TX000045 for pulmonary hypertension from interstitial lung disease

  This study tests TX000045 to see if it can reduce pulmonary vascular resistance in people with PH caused by interstitial lung disease and to check its safety.

  Recruiting at 12 sites Phase 2 Tectonic Operating Company, Inc. · Phoenix, Arizona and 15 other locations · NCT07473700

• 68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases

  This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07464132

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.